Baxter International Stock News

Baxter International Inc. found using ticker (BAX) now have 16 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 110 and 88 and has a mean target at 97. Given that the stocks previous close was at 82.8 this indicates there is a potential upside of 17.1%. The 50 day MA is 85.45 and the 200 day moving average is 81.33. The company has a market capitalisation of $41,232m. Company Website: https://www.baxter.com [stock_market_widget type="chart" template="basic" color="green" assets=BAX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $48,303m based on the market concensus. Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Riding The Stock Waves: Update On The Medical Devices Sector

WASHINGTON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Chemotherapy Devices Market finds that increasing prevalence of cancer is expediting market growth. Primarily driven by increasing cardiovascular surgeries and diagnostics, the total Global Chemotherapy Devices Market is estimated to reach USD 23.12 Billion by 2028 . The Market stood at a revenue of USD 11.54 Billion in the year 2021, and is expected to exhibit a Compound Annual Growth Rate (CAGR) of 7.5%. Furthermore, the increase in technological advancements is also anticipated to augment the growth of the Global Chemotherapy Devices Market, states Vantage Market Research, in a report, titled " Chemotherapy Devices Market by Product (Catheter, Cannula, Pump, Others), by Application (Hospital, Clinics, Home Care), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)". Click Here To Access The Free Sample Report @ https://www.vantagemarketresearch.com/chemotherapy-devices-market-1310/request-sample (The Free Sample Of This Report Is Readily Available On Request).

Over the past 3 months, 6 analysts have published their opinion on Baxter Intl (NYSE: BAX ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 6 0 0 0 Last 30D 0 3 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 3 0 0 0 3M Ago 0 0 0 0 0 According to 6 analyst offering 12-month price targets in the last 3 months, Baxter Intl has an average price target of $100.5 with a Full story available on Benzinga.com

The Baxter (NYSE: BAX) stock is trending today. This is why.

Baxter International Inc (NYSE: BAX ) has posted Q4 revenue of $3.5 billion , beating the consensus of $3.35 billion, up 10% on a reported basis, 12% on a constant currency basis, and 4% on an operational basis. Adjusted EPS of $1.04 increased 30%, marginally ahead of the consensus of $1.03. Following Baxter''s acquisition of Hillrom, Baxter''s Q4 and FY21 results include Hillrom''s financial … Full story available on Benzinga.com

Shares of Baxter International (BAX) are down 3% in premarket trading even though the company quarterly results beat on the top and bottom lines.

Baxter Earnings, Revenue Beat in Q4

Baxter International's (BAX) CEO Joe Almeida on Q4 2021 Results - Earnings Call Transcript

Baxter press release (BAX): Q4 Non-GAAP EPS of $1.04 beats by $0.01.Revenue of $3.51B (+9.7% Y/Y) beats by $160M.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2021, and provided its financial guidance for full-year and first-quarter 2022. Fourth-quarter and full-year 2021 results reflect 19 days of contribution from Hillrom Holdings, Inc. (Hillrom) subsequent to Baxter’s acquisition of the company on Dec. 13, 2021. “In 2021, Baxter’s dedicated employees remained focused on respondi

Baxter's (BAX) fourth-quarter results reflect robust performance across six of its business units.

Baxter International Inc (NYSE: BAX) has posted Q4 revenue of $3.5 billion, beating the consensus of $3.35 billion, up 10% on a reported basis, 12% on a constant currency basis, and 4% on an operati